Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index; 20 of the 61 sources its claims cite were checked for support.

Epidemiology, Staging, and Management of Multiple Myeloma

Open access

Abstract

Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5× risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (>3 g/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.

Overview

CoChat Summary

## TL;DR

This 2021 review summarizes the epidemiology, staging, diagnosis, and management of multiple myeloma, emphasizing that incidence has risen while survival has improved with newer therapies and transplant techniques. It also highlights the major risk groups, current staging systems, and common first-line and relapsed-disease treatment approaches.

## Key findings

  • Global MM burden was estimated at 160,000 cases in 2018 and 106,000 deaths in 2018; MM accounted for 0.9% of all cancer diagnoses and 1.1% of all cancer deaths.
  • From 1990 to 2016, global incidence increased by 126% and global deaths increased by 94%; in the US, incidence rose by 143% since 1975, while mortality fell and 5-year survival increased from 23.7% in 1976 to 53.9% in 2016.
  • Risk is higher in older adults (median diagnosis age 69 in the US), men (about 1.5× higher risk globally), and African Americans (incidence 16.5/100,000 in African American men and 12.0/100,000 in African American women, versus 8.2 and 5.0 in Caucasians).
  • In an international clinical trial with 3,060 participants, 5-year survival by revised ISS stage was 82% for stage I, 62% for stage II, and 40% for stage III.

## Methods

  • Narrative review article describing the “latest review” of MM; the paper states that an extensive literature search was done.
  • Synthesizes epidemiologic data (e.g., GLOBOCAN, SEER), staging systems (ISS, DSS, revised ISS), diagnostic criteria, and treatment evidence from cited trials and studies.
  • Main analysis is descriptive and integrative rather than experimental, comparing published incidence, mortality, risk-factor, staging, and treatment results.

## Limitations

  • The paper does not report a systematic review method, search strategy, or inclusion/exclusion criteria; this is evident from the text (descriptive review), not stated as a limitation by the authors.
  • The evidence base is largely observational and from cited studies/trials across different settings, so direct causal inference is limited; this is evident from the text.
  • Not stated in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/medsci9010003

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Map showing the estimated age-standardized incidence rates per 100,000 (world) in 2018 of multiple myeloma (MM) for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].
Figure 1 Map showing the estimated age-standardized incidence rates per 100,000 (world) in 2018 of multiple myeloma (MM) for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].CC BY · PubMed Central
Figure 2 Map showing the estimated age-standardized mortality rates per 100,000 (world) in 2018 of multiple myeloma for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].
Figure 2 Map showing the estimated age-standardized mortality rates per 100,000 (world) in 2018 of multiple myeloma for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].CC BY · PubMed Central
Figure 3 Graph showing the estimated cumulative risk of incidence in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2. Data obtained from GLOBOCAN 2018 [7].
Figure 3 Graph showing the estimated cumulative risk of incidence in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2. Data obtained from GLOBOCAN 2018 [7].CC BY · PubMed Central
Figure 4 Graph showing the estimated number of prevalent cases (5 year) as a population in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2 Data obtained from GLOBOCAN 2018 [7].
Figure 4 Graph showing the estimated number of prevalent cases (5 year) as a population in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2 Data obtained from GLOBOCAN 2018 [7].CC BY · PubMed Central
Figure 5 Bar chart showing the 5 year age-adjusted mortality rates from 2013–2017 by age for the United States. Created with Tableau 2019.2. Data source: SEER*Explorer [11].
Figure 5 Bar chart showing the 5 year age-adjusted mortality rates from 2013–2017 by age for the United States. Created with Tableau 2019.2. Data source: SEER*Explorer [11].CC BY · PubMed Central
Figure 6 Bar chart showing the United States’ 5-year age-adjusted mortality rates from 2013–2017 for all races (including Hispanics). Created with Tableau 2019.2. Data source: SEER*Explorer [11].
Figure 6 Bar chart showing the United States’ 5-year age-adjusted mortality rates from 2013–2017 for all races (including Hispanics). Created with Tableau 2019.2. Data source: SEER*Explorer [11].CC BY · PubMed Central
Figure 7 Modified flow chart depicting the general outline of treatment options for MM adopted from mSMART.org. HCT: hematopoietic stem cell transplantation.
Figure 7 Modified flow chart depicting the general outline of treatment options for MM adopted from mSMART.org. HCT: hematopoietic stem cell transplantation.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 12 Not valid · 30 Not checked · 10 Own results and interpretations

15 more claims · 1 with their cited sources checked

Create a free account to see all 66 claims and to verify the 19 references still open.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 30
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 3

  1. Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review 1975–2016.
  2. Vakiti, A., Padala, S.A., and Mewawalla, P. (2020, May 07). Myeloma Kidney, Available online: https://www.ncbi.nlm.nih.gov/books/NBK499952/.
  3. Vakiti, A., and Mewawalla, P. (2020, May 07). Malignancy-Related Hypercalcemia, Available online: https://www.ncbi.nlm.nih.gov/books/NBK482423/.

Cited by

See all 332

Metadata

Authors
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H.
Affiliations
  • Augusta University (US)
  • Allegheny Health Network (US)
  • Sovah Health Martinsville (US)
Corresponding author
Padala, Sandeep Anand
Venue
Medical Sciences
Publisher
MDPI AG
Published
2021-01-20
Volume
9
Issue
1
Pages
3
ISSN
2076-3271 (ISSN-L)
OpenAlex
W3125352349
Cited by
332
References
56
Citations by year
2026: 51 · 2025: 84 · 2024: 87 · 2023: 66 · 2022: 38 · 2021: 5
FWCI
8.58
Type
journal article
Language
en
Open access
Locations
  • Medical Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, incidence and mortality trends, risk factors, M protein, International Staging System, beta2-microglobulin, lactate dehydrogenase, chromosomal abnormalities, hematopoietic stem cell transplantation, bisphosphonates, skeletal-related events, relapsed multiple myeloma, daratumumab, proteasome inhibitors, immunomodulating agents, CAR T-cell therapy, BCMA, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma
MeSH terms
Immunomodulating Agents, Anemia, Humans, Hypercalcemia, Multiple Myeloma, Pain, Paraproteinemias, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology, Staging, and Management of Multiple Myeloma. https://app.cochat.ai/papers/10.3390/medsci9010003
The paper
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Medical Sciences. https://doi.org/10.3390/medsci9010003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.